AMGN at a glance
Amgen (AMGN, SEC CIK 318154) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as August 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Amgen (AMGN) reported revenue of $36.8 billion (up 10.0% from FY2024) and net income of $7.7 billion. Diluted EPS was $14.23.
- As of June 30, 2026, 63 institutional investment managers tracked by SignalX reported holding Amgen (AMGN) shares worth $77.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Khosla Rachna on August 13, 2026 of 1,252 shares at $416.43 per share.
- In the last 90 days, AMGN insiders reported 0 open-market purchases ($0) and 6 open-market sales ($4.1M) on Form 4, a net sale of $4.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $36.8B
- +10.0% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$4.1M
- 13F holders
- 63 funds
- $77.8B · +0 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
- NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023
- Strategic shift: Acquisition of Horizon Therapeutics with stock plans merged, ending Horizon plans for future grants as of Oct 6, 2023
- Quantitative metric: 11,230,989 total securities issuable under Amgen and acquired equity plans, weighted-average exercise price $234.45
- Noteworthy fact: Performance units granted in 2023-2025 can yield up to 200% of target shares based on performance goals
Management Discussion & Analysis
- Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
- Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024
- Dividends per share increased 6% YoY to $2.38 in 2025 from $2.25 in 2024
- No stock repurchases in 2025, $200M repurchased in 2024, $6.8B repurchase authorization remains
- Management confident in liquidity from operations, debt markets, and existing cash for capital needs and shareholder returns
Risk Factors
- Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
- Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals
- Supply chain/operational vulnerability: Multi-jurisdictional patent litigation delays marketing; UPC actions and EPO oppositions prolong product launches like Repatha and PAVBLU
- Competitive risk: Multiple biosimilar patent infringement lawsuits filed against five companies including Amneal, Hikma, Dr. Reddy’s, Alkem seeking to enter U.S. market for Prolia/XGEVA
- Financial risk: $1.8B final U.S. repatriation tax payment made in 2025 under 2017 Tax Act, material cash outflow impacting liquidity planning
AI summary of the AMGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Repatha revenue $953M, up 37% YoY, driven by volume growth
- Prolia revenue $759M, down 32% YoY, worst-performing product
- Prolia volume down 20%; net selling price down 12%
- Prolia sales erosion expected to accelerate through 2026 amid biosimilar competition
Risk Factors
- New PFAS regulatory exposure, triggered by proposed EU pharmaceutical manufacturing and packaging ban
- Manufacturing and distribution disruption risk, concentrated at Louisville and Breda centers
- Regulatory approval delays from manufacturing-line quality findings extending to unrelated facilities
- Supply-chain dependence on third-party manufacturers and logistics providers, with alternatives potentially unavailable
- U.S.-focused drug-manufacturing legislation risk, including proposed Veterans Affairs purchasing restrictions on foreign APIs
AI summary of the AMGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 and six-month 2026 unaudited results released August 4, 2026; full financial details in Exhibit 99.1
- Investor focus on GAAP-to-non-GAAP reconciliation, including EPS, operating margin, expenses and tax rate
Item 1.05: Material Cybersecurity Incidents
- Filing signed July 31, 2026 by Jonathan P. Graham
- Graham identified as Amgen’s Executive Vice President, General Counsel and Secretary
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 12 director nominees elected to one-year terms expiring at the 2027 annual meeting
- Executive compensation approved with 399,315,381 votes for versus 11,987,682 against
AI summaries of AMGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AMGN
Don't miss the next AMGN filing
- Alerts as it files. A push when AMGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AMGN, by share count.
- Ask anything. An AI agent that reads every AMGN filing and answers with sources.
AMGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Khosla Rachna | M | Aug 13, 2026 | 1,252 | - |
| Khosla Rachna | Sell | Aug 13, 2026 | 1,252 | $416.43 |
| Khosla Rachna | M | Aug 13, 2026 | 1,252 | $162.60 |
| Khosla Rachna | Sell | Aug 11, 2026 | 2,000 | $412.57 |
| HOLLEY CHARLES M | A | Aug 7, 2026 | 103.419 | - |
| Drake Michael V | A | Aug 7, 2026 | 63.876 | - |
| Busch Matthew C. | A | Aug 7, 2026 | 730 | - |
| ISHRAK OMAR | A | Aug 7, 2026 | 85.169 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $33.4B | $36.8B |
| Operating Income | - | $7.3B | $9.1B |
| Net Income | $6.7B | $4.1B | $7.7B |
| Op. Margin | - | 21.7% | 24.7% |
| Net Margin | - | 12.2% | 21.0% |
| Balance Sheet | |||
| Total Assets | $97.2B | $91.8B | $90.6B |
| Equity | - | $5.9B | $8.7B |
| ROE | - | 69.6% | 89.1% |
| Per Share | |||
| EPS | $12.49 | $7.56 | $14.23 |
| Cash Flow | |||
| Operating CF | - | $11.5B | $10.0B |
| CapEx | $1.1B | $1.1B | $1.9B |
Source: XBRL data in Amgen (AMGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AMGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 63 | $77.81B |
| Q1 2026 | 63 | $75.01B |
| Q4 2025 | 61 | $70.92B |
| Q3 2025 | 64 | $59.06B |
| Q2 2025 | 64 | $57.96B |
| Q1 2025 | 61 | $49.52B |
| Q4 2024 | 58 | $33.96B |
| Q3 2024 | 53 | $21.68B |
- BlackRock+2.26M (+5%)
- T. Rowe Price Group+2.09M (+112%)
- D.E. Shaw & Co+1.11M (+625%)
- Two Sigma Investments+1.06M (+1475%)
- Citadel Advisors LLC+519.0K (+281%)
- JPMorgan Chase & Co−3.69M (-51%)
- Morgan Stanley−2.18M (-14%)
- FMR LLC (Fidelity)−284.6K (-8%)
- Millennium Management−150.7K (-66%)
- Franklin Resources−135.0K (-9%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 487 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AMGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 19, 2026 | - | Analysis | |
| SC 13G | May 14, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 7, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
AMGN SEC filings: frequently asked questions
Are AMGN insiders buying or selling?
In the last 90 days, Amgen (AMGN) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $4.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AMGN stock?
As of June 30, 2026, the largest Amgen (AMGN) holders among the 13F filers tracked by SignalX were BlackRock ($17.9 billion), Vanguard Capital Management LLC ($12.8 billion), State Street Corp ($11.1 billion), Invesco Ltd ($5.9 billion), Vanguard Portfolio Management LLC ($5.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AMGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Amgen (AMGN) reported revenue of $36.8 billion (up 10.0% from FY2024) and net income of $7.7 billion. Diluted EPS was $14.23. The figures come from the XBRL data in the 10-K.
What are the main risks in AMGN's latest 10-K?
In the 10-K filed February 13, 2026, Amgen (AMGN) flagged: Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages. Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals. (AI summary of the Risk Factors section.)
What did AMGN report in its latest 8-K?
Amgen (AMGN) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and six-month 2026 unaudited results released August 4, 2026; full financial details in Exhibit 99.1.
What are the latest AMGN SEC filings?
Amgen (AMGN) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on August 13, 2026.
What is AMGN's SEC CIK number?
Amgen (AMGN)'s SEC Central Index Key (CIK) is 318154. EDGAR lists every AMGN filing under that number.
Ask anything about AMGN
The research agent reads AMGN's filings, financials, insider trades and 13F holders, then answers with sources.